Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

According to Bank of America, several companies are prime candidates for a stock split in the near future, which could lead ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

The increase in weight loss with the higher dose was impressive, but still lower than has been achieved in clinical trials of Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...

While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...